Wardhana A, Valeria M
Plastic Reconstructive and Aesthetic Surgery Division & Burn Unit, Department of Surgery, Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Ann Burns Fire Disasters. 2022 Sep 30;35(3):227-236.
The early management of burn cases has always been a challenging medical problem. Skin substitutes have been consistently studied and employed as the prospective treatment modality for burn cases worldwide. However, this treatment method remains uncommon in many developing countries. This systematic review is designed to weigh the efficacy of skin substitutes compared to standard treatment for managing acute burn cases. A literature search was conducted using PubMed, Scopus and Cochrane database up to February 2020 combined with additional reference searching. Studies were restricted to randomized controlled trials (RCTs), with no date and language restrictions. We evaluated the risk of bias with a revised risk of bias tool for randomized trials (RoB2). Data were categorized based on skin substitutes with further subgroup analysis for each skin substitute. We included 13 studies with six types of skin substitutes, Biobrane®, TransCyte ®, Integra®, Glyaderm®, Suprathel® and Apligraft®. Outcomes measured included wound healing time, pain, length of hospitalization and scar formation. The findings for all skin substitutes demonstrated less severe pain compared to the control group. Faster wound healing time, scar formation and length of hospitalization were identified as heterogeneous depending on the type of skin substitutes used. All of the skin substitutes studied exhibited at least non-inferior to superior performance compared to standard treatment in terms of efficacy in treating acute burn wounds, not limited to burn depth, size, location or patient age.
烧伤病例的早期处理一直是一个具有挑战性的医学问题。皮肤替代物一直是全球范围内烧伤病例前瞻性治疗方式的研究和应用对象。然而,这种治疗方法在许多发展中国家仍然不常见。本系统评价旨在权衡皮肤替代物与标准治疗相比在处理急性烧伤病例方面的疗效。截至2020年2月,使用PubMed、Scopus和Cochrane数据库进行了文献检索,并结合了额外的参考文献检索。研究仅限于随机对照试验(RCT),没有日期和语言限制。我们使用修订后的随机试验偏倚风险工具(RoB2)评估偏倚风险。数据根据皮肤替代物进行分类,并对每种皮肤替代物进行进一步的亚组分析。我们纳入了13项研究,涉及六种皮肤替代物,即生物皮肤(Biobrane®)、TransCyte®、人工真皮(Integra®)、优色林(Glyaderm®)、Suprathel®和爱皮康(Apligraft®)。测量的结果包括伤口愈合时间、疼痛、住院时间和瘢痕形成。所有皮肤替代物的研究结果显示,与对照组相比疼痛较轻。根据所使用的皮肤替代物类型,伤口愈合时间、瘢痕形成和住院时间的加快被确定为异质性。在所研究的所有皮肤替代物中,就治疗急性烧伤创面的疗效而言,至少表现出与标准治疗相当或更优的性能,且不限于烧伤深度、大小、部位或患者年龄。